Nef modulation of HIV type 1 gene expression and cytopathicity in tissues of HIV transgenic mice

AIDS Research and Human Retroviruses

Volumn 16, Issue 8, 2000, Pages 777-790

  Dickie, Peter ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; MUTANT PROTEIN; NEF PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; GENE EXPRESSION REGULATION; HIV ASSOCIATED NEPHROPATHY; HUMAN IMMUNODEFICIENCY VIRUS 1; KIDNEY DISEASE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TRANSGENE; TRANSGENIC MOUSE; VIRUS GENE;

ANIMALS; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, NEF; GENES, NEF; GENOTYPE; HIV INFECTIONS; HIV-1; KIDNEY; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MICE; MICE, TRANSGENIC;

EID: 0034690773     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200308774     Document Type: Article

References (51)

1. 1. Trono D: HIV accessory proteins: Leading roles for the supporting cast. Cell 1995;82:189-192.
2. 2. Vandendriessche T, Chuah MK, Chiang L, Chang HK, Ensoli B, and Morgan RA: Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary T lymphocytes by retroviral vectors expressing anti-HIV genes. J Virol 1995;69:4045-4052.
3. 3. Gervaiz A, Li X, and Wong-Staal F: Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J Virol 1997;71:3048-3053.
4. 4. Donahue RE, Bunnell BA, Zink MC, Metzger ME, Westro RP, Kirby MR, Unangst T, Clements JE, and Morgan RA: Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes. Nature Med 1998;4: 181-186.
5. 5. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, and Desrosiers RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:1938-1941.
6. 6. Deacon NJ, Solomon AA, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, Lawson VA, Crowe S, Maerz A, Sonza S, Learmont J, Sullivan JS, Cunningham A, Dwyer D, Dowton D, and Mills J: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995;270:988-991.
7. 7. Michael NL, Chang G, D'Arcy LA, Ehrenberg PK, Mariani R, Busch MP, Birx DL, and Schwartz DH: Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus. J Virol 1995;69:4228-4236.
8. 8. Garcia JV and Miller AD: Serine phosphorylation-independent downregulation of cell-surface CD4 by Nef. Nature (London) 1991;350:508-511.
9. 9. Schwartz O, Marechal V, Le Gall S, Lemonnier F, and Heard JM: Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nature Med 1996;2:338-342.
10. 10. Xu XN, Screaton GR, Gotch FM, Dong T, Tan R, Almond N, Walker B, Stebbings R, Kent K, Nagata S, Stott JE, and McMichael AJ: Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells. J Exp Med 1997;186:7-16.
11. 11. Greenway A, Azad A, and McPhee D: Human immunodeficiency virus type 1 Nef protein inhibits activation pathways in peripheral blood mononuclear cells and T cell lines. J Virol 1995;69: 1842-1850.
12. 12. Collins KL, Chen BK, Kalams SA, Walker BD, and Baltimore D: HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature (London) 1998;391:397-401.
13. 13. Ahmed R and Stevens JG: Viral persistence. In: Fundamental Virology (Fields BN and Knipe DM, eds.). Raven Press, New York, 1991, pp. 241-266.
14. 14. Garcia-Blanco MA and Cullen BR: Molecular basis of latency in pathogenic human viruses. Science 1991;254:815-819.
15. 15. Fauci AS: Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 1993;262:1011-1018.
16. 16. Coffin J: HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 1995;267: 483-489.
17. 17. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, and Siliciano RF: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
18. 18. Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, and Jolicoeur P: Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 1998;95:163-175.
19. 19. Thomas FP, Chalk C, LaLonde R, Robitaille Y, and Jolicoeur P: Expression of human immunodeficiency virus type 1 in the nervous system of transgenic mice leads to neurological disease. J Virol 1994;68:7099-7107.
20. 20. Gazzinelli RT, Sher A, Cheever A, Gerstberger S, Martin MA, and Dickie P: Infection of human immunodeficiency virus 1 transgenic mice with Toxoplasma gondii stimulates proviral transcription in macrophages in vivo. J Exp Med 1996;183:1645-1655.
21. 21. Tinkle BT, Ueda H, Ngo L, Luciw PA, Shaw K, Rosen CA, and Jay G: Transgenic dissection of HIV genes involved in lymphoid depletion. J Clin Invest 1997;100:32-39.
22. 22. Pomerantz RJ, Trono D, Feinberg MB, and Baltimore D: Cells non-productively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency. Cell 1990;61: 1271-1276.
23. 23. Dickie P, Felser J, Eckhaus M, Bryant J, Silver J, Marinos N, and Notkins AL: HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology 1991;185:109-119.
24. 24. Dickie P, Ramsdell F, Notkins AL, and Venkatesan S: Spontaneous and inducible epidermal hyperplasia in transgenic mice expressing HIV-1 Nef. Virology 1993;197:431-438.
25. 25. Dickie P: HIV-1 Nef perturbs eye lens development in transgenic mice. AIDS Res Hum Retroviruses 1996;12:177-189.
26. 26. Jamieson BD, Aldrovandi GM, Planelles V, Jowett JBM, Gao L, Bloch LM, Chen ISY, and Zack JA: Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J Virol 1994;68:3478-3485.
27. 27. Miller MD, Warmerdam MT, Gaston I, Greene WC, and Feinberg MB: The human immunodeficiency virus-1 nef gene product: A positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 1994;179:101-113.
28. 28. Saksela K, Cheng G, and Baltimore D: Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4. EMBO J 1995;14:484-491.
29. 29. Sawai ET, Baur A, Struble H, Peterlin BM, Levy JA, and Cheng-Mayer C: Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes. Proc Natl Acad Sci USA 1994;91:1539-1543.
30. 30. Greenway A, Azad A, Mills J, and McPhee D: Human immunodeficiency virus type 1 Nef binds directly to Lck and mitogen-activated protein kinase, inhibiting kinase activity. J Virol 1996;70: 6701-6708.
31. 31. Moarefi I, LaFevre-Bernt M, Sicheri F, Huse M, Lee CH, Kuriyan J, and Miller WT: Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature (London) 1997;385:650-653.
32. 32. Harris M: From negative factor to a critical role in virus pathogenesis: The changing fortunes of Nef. J Gen Virol 1996;77: 2379-2392.
33. 33. Skowronski J, Parks D, and Mariani R: Altered T cell activation and development in transgenic mice expressing the HIV-1 gene. EMBO J 1993;12:703-713.
34. 34. Crowe SM and Kornbluth RS: Overview of HIV interactions with macrophages and dendritic cells: The other infection in AIDS. J Leukocyte Biol 1995;56:215-217.
35. 35. De SK, Venkateshan CN, Seth P, Gajdusek DC, and Gibbs CJ: Adenovirus-mediated human immunodeficiency virus-1 Nef expression in human monocytes/macrophages and effect of Nef on downmodulation of Fcgamma receptors and expression of monokines. Blood 1998;91:2108-2117.
36. 36. Bolen JB: Nonreceptor tyrosine protein kinases. Oncogene 1993;8:2025-2031.
37. 37. Felser JM, Klimkait T, and Silver J: A syncytia assay for human immunodeficiency virus type 1 (HIV-1) envelope protein and its use in studying HIV-1 mutations. Virology 1989;170:566-570.
38. 38. Hogan B, Costantini F, and Lacy E: Manipulating the Mouse Embryo. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1986.
39. 39. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
40. 40. Klotman ME, Kim S, Buchbinder A, DeRossi A, Baltimore D, and Wong-Staal F: Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc Natl Acad Sci USA 1991;88: 5011-5015.
41. 41. Kajiyama W, Kopp JB, Marinos NJ, Klotman PE, and Dickie P: HIV-transgenic mice lacking gag-pol-nef develop glomerulosclerosis and express viral RNA and protein in glomerular epithelial and tubular cells. Kidney Int 2000; in press.
42. 42. Santoro TJ, Bryant JL, Pellicoro J, Klotman ME, Kopp JB, Brugeman LA, Franks RR, Notkins AL, and Klotman PE: Growth failure and AIDS-like cachexia syndrome in HIV-1 transgenic mice. Virology 1994;201:147-151.
43. 43. Leonard JM, Abramczuk JW, Pezen DS, Rutledge R, Belcher JH, Hakim F, Shearer G, Lamperth L, Travis W, Fredrickson T, Notkins AL, and Martin MA: Development of disease and virus recovery in transgenic mice containing HIV proviral DNA. Science 1988;242:1665-1670.
44. 44. Plasman N and Vray B: Mouse peritoneal macrophages: Characterization of functional subsets following Percoll density gradients. Res Immunol 1993;144:151-163.
45. 45. Seney FD, Burns DK, and Silva FG: Acquired immunodeficiency syndrome and the kidney. Am J Kidney Dis 1990;16:1-13.
46. 46. Vogel J, Hinrichs SH, Reynolds RK, Luciw PA, and Jay G: The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature (London) 1988;335:606-611.
47. 47. Hanna Z, Kay DG, Cool M, Jothy S, Rebai N, and Jolicoeur P: Transgenic mice expressing human immunodeficiency virus type 1 in immune cells develop a severe AIDS-like disease. J Virol 1998;72:121-132.
48. 48. Dickie P, Gazzinelli R, and Chang L-J: Models of HIV type 1 proviral gene expression in wild-type HIV and MLV/HIV transgenic mice. AIDS Res Hum Retroviruses 1996;12:1103-1116.
49. 49. Murphy KM, Sweet MJ, Ross IL, and Hume DA: Effects of the tat and nef gene products of human immunodeficiency virus type 1 (HIV-1) on transcription controlled by the HIV-1 long terminal repeat and on cell growth in macrophages. J Virol 1993;67: 6956-6964.
50. 50. Richard A, Robichaud G, Lapointe R, Bourgoin S, Darveau A, and Poulin L: Interference of HIV-1 Nef in the sphingomyelin transduction pathway activated by tumour necrosis factor-α in human glial cells. AIDS 1996;11:F1-F7.
51. 51. Yoo J, Chen H, Kraus T, Hirsch D, Polyak S, George I, and Sperber K: Altered cytokine production and accessory cell function after HIV-1 infection. J Immunol 1996;157:1313-1320.